Randomisation Program

Call Freefone 0800 138 5451 to contact the RECOVERY team for URGENT problems using the Randomisation Program or for medical advice. All NON-URGENT queries should be emailed to recoverytrial@ndph.ox.ac.uk

	Logged in as: RECOVERY Site
	Section A: Baseline and Eligibility
	Date and time of randomisation: 30 Dec 2021 14:00
Treating clinician A1. Name of treating clinician	
Patient details	
A2, Patient surname	
Patient forename	
A3. NHS number	☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐
A4. What is the patient's date of birth?	01 V / January V / 2019 V Age: 2y 11m
A4.3 What is this child's weight? Use estimated weight if necessary	kg
A5. What is the patient's sex?	
Inclusion criteria A6. Has consent been taken in line with the protocol? If answer is No patient cannot be enrolled in the study NB current PTS/ICE version is VI.9.1 (adults) or VI.3.1 (children)	_
A6.0 How was consent obtained?	
A6.5 Does this patient have viral pneumonia? See protocel for typical features. If answer is No patient cannot be enrolled in the study (unless they are a child with PIMS-TS)	Yes v
A7.0 Does the patient have proven SARS-CoV-2 infection?	Yes
A7.0.1 What was lateral flow test result?	
A7.0.2 What was PCR test result?	V
A7.1 Does the patient have proven influenza infection?	<u> </u>
A7.5 Does the patient have probable PIMS-TS syndrome?	Yes v
A8. Does the patient have any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial?	
A9. Symptom onset date:	~/ ~/ ~
A10. Date of hospitalisation:	v / v / v
A11. Does the patient require oxygen?	V
A12. Please select one of the following to describe the current level of ventilation support	٧
A12.1 Enter latest oxygen saturation measurement (%)	
A12.2 Enter latest CRP measurement since admission to hospital (mg/L) Enter 0 if below the limit of measurement	☐ Tick if not measured ☐ Tick if greater than limit of measurement
A12.3 Enter latest creatinine measurement since admission to hospital	µmel/L ∨ □Tick if not measured
A12.4 Enter latest D-dimer measurement since admission	
to hospital Enter 0 if below the limit of measurement	☐ Tick if greater than Jimit of measurement
A12.5 Has the patient received a COVID-19 vaccine?	v
A12.6 Has the patient received an influenza vaccine in the last 12 months?	
Does the patient have any CURRENT comorbidities or A13.1 Diabetes	other medical problems or treatments?
A13.2 Heart disease	V
A13.3 Chronic lung disease	V
A13.4 Tuberculosis	V
A13.5 HIV	<u> </u>
A13.6 Severe liver disease	•
A13.7 Severe kidney impairment (eGFR<30 or on dialysis)	
A13.9.0 Does their clinician consider the patient to be	
severely immunocompromised? A13.12 Has the patient received tocilizumab or	
sarilumab therapy during this admission? A13.14 Current or planned treatment with neuraminidase inhibitor	<u> </u>
eg, oseltamivir, zanamivir A13.15 Has the patient received	
casirivimab+imdevimab (Ronapreve) during this illness?	
A13.16 Has the patient received sotrovimab during this illness?	
A13.17 Has the patient received molnupiravir during this illness?	
Are the following treatments UNSUITABLE for the p If you answer Yes it means you think this patient sho Are the following treatments available? Current medication	atient? Ilid NOT receive this drug.
A16.1 Is the patient currently prescribed remdesivir?	
A16.2 Is the patient currently prescribed systemic corticosteroids (dexamethasone, prednisolone), hydrocortisone, methy iprednisolone)? Hease do not include topical or inhaled treatments	
A16.5 What venous thromboembolism prophylaxis is the patient receiving? Standard – usual for hospitalsed patients (not increased due to COVID-19); Higher dose – treatment dose or increased prophylaxis due to COVID-19 Please sign off this form once complete	
Surname:	
Forename:	
Professional email:	
	Cancel